Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation.

In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention. 

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure. 

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS). 

 
Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib. 

 Subscribe to Eagle's Eye View